Prague Med. Rep. 2021, 122, 257-268
https://doi.org/10.14712/23362936.2021.23
Short Review of Liposteroid: A Novel Targeted Glucocorticoid Preparation for Treatment of Autoimmune and Inflammatory Diseases
References
1. 1993) Liposome-incorporated dexamethasone palmitate: Chemical and physical properties. Int. J. Pharm. 89(3), 157–167.
< , H., De Gand, G., Brasseur, R., Van Vooren, J. P., Legros, F. J. (https://doi.org/10.1016/0378-5173(93)90239-C>
2. 2017) Idiopathic pulmonary hemosiderosis in adults: Review of cases reported in the latest 15 years. Clin. Respir. J. 11(6), 677–681.
< , X.-Y., Sun, J.-M., Huang, X.-J. (https://doi.org/10.1111/crj.12440>
3. 2013) Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. Eur. J. Pediatr. 172(11), 1475–1481.
< , T., Ohga, S., Ishimura, M., Takada, H., Ishii, K., Ihara, K., Nagai, H., Hara, T. (https://doi.org/10.1007/s00431-013-2065-9>
4. 2015) Erratum to: Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. Eur. J. Pediatr. 174(12), 1701–1701.
< , T., Ohga, S., Ishimura, M., Takada, H., Ishii, K., Ihara, K., Nagai, H., Hara, T. (https://doi.org/10.1007/s00431-015-2638-x>
5. 2010) Histiocytic disorders: Recent insights into pathophysiology and practical guidelines. Biol. Blood Marrow Transplant. 16, S82–S89 (Suppl. 1).
< , A., McClain, K., Grom, A. (https://doi.org/10.1016/j.bbmt.2009.11.014>
6. 2003) Effects of liposteroid on the hemophagocytic syndrome in systemic lupus erythematosus. Lupus 12(6), 483–485.
< , M., Ohno, M., Yamagata, T., Nozaki, Y., Kinoshita, K., Kanamaru, A. (https://doi.org/10.1191/0961203303lu373oa>
7. Furst, D. E., Saag, K. G. (2020) Determinants of glucocorticoid dosing. UpToDate.
8. Gregoriadis, G., Senior, J., Wolff, B., Kirby, C. (1984) Fate of liposomes in vivo: Control leading to targeting. In: Receptor-mediated Targeting of Drugs. Gregoriadis, G., Poste, G., Senior, J., Trouet, A., pp. 243–266, Plenum Press, New York.
9. 1985) Double-blind study with liposteroid in rheumatoid arthritis. Drugs Exp. Clin. Res. 11(9), 621–626.
, K., Mizushima, Y., Shiokawa, Y., Kageyama, T., Honma, M., Kashiwazaki, S., Shichikawa, K., Tsunematsu, T., Kaneko, K. (
10. 1988) Comparative pharmacokinetic study of dexamethasone disodium phosphate in chronic rheumatoid arthritis patients. Yakuri to Chiryo 16, 865.
, S., Okamoto, H., Yokoyama, K., Suyama, T. (
11. 2007) Successful treatment with liposteroid followed by reduced intensity stem cell transplantation in an infant with perforin deficiency presenting with hemophagocytic lymphohistiocytosis. J. Pediatr. Hematol. Oncol. 29(3), 178–182.
< , Y., Salih, H. M., Kajiume, T., Nakamura, K., Miyagawa, S., Sato, T., Nishimura, S., Kobayashi, M. (https://doi.org/10.1097/MPH.0b013e3180335030>
12. 2020) Dexamethasone palmitate is a feasible option for the treatment of chronic graft-vs-host disease, particularly with macrophage hyperactivation. Pediatr. Transplant. 24(1), e13627.
< , Y., Morita, D., Shibazaki, T., Komori, K., Motobayashi, M., Shigemura, T., Tanaka, M., Nakazawa, Y. (https://doi.org/10.1111/petr.13627>
13. 1982) Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann. Paediatr. Rheumatol. 41(3), 263–267.
, Y., Hamano, T., Yokoyama, K. (
14. 1983) Targeting steroid therapy in rheumatoid arthritis. Ann. Rheum. Dis. 42(4), 479–480.
< , Y., Kaneko, K., Hoshi, K. (https://doi.org/10.1136/ard.42.4.479>
15. 2000) Molecular mechanisms of glucocorticoid action: What is important? Thorax 55(7), 603–613.
< , R. (https://doi.org/10.1136/thorax.55.7.603>
16. 2009) Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: A clue to refractory graft-versus-host disease. Blood 114(14), 3113–3116.
< , S., Terakura, S., Ito, M., Goto, T., Seto, A., Watanabe, K., Yanagisawa, M., Imahashi, N., Tsukamoto, S., Shimba, M., Ozawa, Y., Miyamura, K. (https://doi.org/10.1182/blood-2009-03-209635>
17. 2014) Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functions. PLoS One 9(5), e96252.
< , S., Nakayama, T., Murata, M., Nishida, T., Terakura, S., Saito, S., Kato, T., Mizuno, H., Imahashi, N., Seto, A., Ozawa, Y., Miyamura, K., Ito, M., Takeshita, K., Kato, H., Toyokuni, S., Nagao, K., Ueda, R., Naoe, T. (https://doi.org/10.1371/journal.pone.0096252>
18. 1979) Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary. Cancer 44(2), 414–423.
< , R. A., McCaffrey, J. A., Polio, J., Clouse, M. E., Lpn, T. H. (https://doi.org/10.1002/1097-0142(197908)44:2<414::AID-CNCR2820440207>3.0.CO;2-3>
19. 1995) Idiopathic pulmonary haemosiderosis in Japan: 39 possible cases from a survey questionnaire. Eur. J. Pediatr. 154(12), 994–995.
< , S., Takahashi, K., Miyazaki, S., Kato, H., Ueda, K. (https://doi.org/10.1007/BF01958645>
20. RECOVERY Collaborative Group; 2021) Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384(8), 693–704.
, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell, L. C., Faust, S. N., Jaki, T., Jeffery, K., Montgomery, A., Rowan, K., Juszczak, E., Baillie, J. K., Haynes, R., Landray, M. J. (
21. 2000) Prevention of hepatic artery occlusion during continuous infusion of fluorouracil using liposteroid. AJR Am. J. Roentgenol. 175(6), 1641–1642.
< , S., Suzuki, T., Tokunaga, N., Tajima, T., Makuuchi, H., Ohtaki, M. (https://doi.org/10.2214/ajr.175.6.1751641>
22. 2020) Idiopathic pulmonary hemosiderosis: A state of the art review. Respir. Med. 176, 106234.
< , B. K. (https://doi.org/10.1016/j.rmed.2020.106234>
23. 2021) Is it time to call idiopathic pulmonary hemosiderosis by the correct name: Immune-mediated pulmonary hemosiderosis? Am. J. Med. Sci. 361(6), 809–811.
< , B. K. (https://doi.org/10.1016/j.amjms.2021.01.006>
24. 2021) Diffuse alveolar hemorrhage in cardiac diseases. Lung 199(2), 103–112.
< , B. K., Chong, W. H. (https://doi.org/10.1007/s00408-021-00433-x>
25. 2021) Idiopathic pulmonary hemosiderosis: A review of the treatments used during the past 30 years and future directions. Clin. Rheumatol. 40(7), 2547–2557.
< , B. K., Milman, N. T. (https://doi.org/10.1007/s10067-020-05507-4>
26. 2020) Antimalarials as antivirals for COVID-19: Believe it or not! Am. J. Med. Sci. 360(6), 618–630.
< , B. K., Bonnier, A., Chong, W. (https://doi.org/10.1016/j.amjms.2020.08.019>
27. 2018) Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis. Respir. Med. Case Rep. 24, 22–24.
, R., Matsumoto, S., Mitsubuchi, H., Nakamura, K. (
28. 1999) Liposteroid therapy for chronic childhood idiopathic thrombocytopenic purpura: Two case reports. Int. J. Pediatr. Hematol. Oncol. 6, 27–31.
, Y., Ohkubo, Y., Miura, S., Mariko, M., Akazawa, H., Imanaka, Y., Kinoshita, S., Yoshioka, A. (
29. 2006) Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer. J. Liposome Res. 16(3), 185–194.
< , R. M., Banciu, M., Metselaar, J. M., Storm, G. (https://doi.org/10.1080/08982100600851029>
30. 2009) Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients. Can. Fam. Physician 55(7), 704–706.
, A. E., Goldman, R. D. (
31. 1996) Treatment for gouty arthriti. Nihon Rinsho 54(12), 3267–3271. (in Japanese)
, T. (
32. 1992) Fluorescent probe-labeled lipid microsphere uptake by human endothelial cells: A flow cytometric study. Jpn. J. Pharmacol. 60(4), 349–356.
< , K., Takahashi, K., Matsuki, Y., Kawakami, M., Kawaguchi, Y., Hidaka, T., Sekiyama, Y., Mizukami, Y., Kawagoe, M., Nakamura, H. (https://doi.org/10.1254/jjp.60.349>
33. 2020) Successful liposteroid therapy for a recurrent idiopathic pulmonary hemosiderosis with Down syndrome. Case Rep. Pediatr. 2020, 1–5.
< , H., Yano, J., Sato, N., Amanuma, F., Takahashi, M., Endo, M., Ishimura, M., Ohga, S., Maruyama, H. (https://doi.org/10.1155/2020/5292947>
34. 1992) Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood 79(1), 45–51.
< , A., Meier, R., Seitz, M., Dewald, B., Baggiolini, M., Fey, M. F. (https://doi.org/10.1182/blood.V79.1.45.45>
35. 2014) Liposomes: An overview. J. Drug Deliv. Ther. 4, 47–55.
, P., Sharma, S. (
36. 2017) Liposteroid therapy for juvenile and adult dermatomyositis: Efficacy and side effects. Ann. Transl. Med. 5(5), 110.
< , H. (https://doi.org/10.21037/atm.2017.01.36>
37. 2016) Clinical utility of the liposteroid therapy: Potential effects on the macrophage activation. Nihon Rinsho Meneki Gakkai Kaishi 39(3), 190–196.
< , H., Ohga, S. (https://doi.org/10.2177/jsci.39.190>
38. 2015) Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: Distinct kinetics of interleukin-6 and -18 levels. Pediatr. Rheumatol. Online J. 13, 49.
< , H., Hasegawa, S., Hirano, R., Kaneyasu, H., Wakabayashi-Takahara, M., Ohga, S. (https://doi.org/10.1186/s12969-015-0048-2>
39. 1998) Liposteroid (dexamethasone palmitate) therapy for West syndrome: A comparative study with ACTH therapy. Pediatr. Neurol. 18(5), 415–419.
< , H., Asoh, M., Murakami, H., Kamiyama, N., Ohta, C. (https://doi.org/10.1016/S0887-8994(98)00003-4>
40. 2007) A new trial liposteroid (dexamethasone palmitate) therapy for intractable epileptic seizures in infancy. Brain Dev. 29(7), 421–424.
< , H., Fukuda, M., Miyamoto, Y., Murakami, H., Kamiyama, N. (https://doi.org/10.1016/j.braindev.2006.12.002>
41. 1996) Limethason as a lipid microsphere preparation: An overview. Adv. Drug Deliv. Rev. 20(2), 195–201.
< , K., Watanabe, M. (https://doi.org/10.1016/0169-409X(95)00122-N>
42. 1985) Development of a corticosteroid incorporated in lipid microspheres (liposteroid). Drugs Exp. Clin. Res. 11(9), 611–620.
, K., Okamoto, H., Watanabe, M., Suyama, T., Mizushima, Y. (
43. 2000) Liposteroid therapy for refractory seizures in children. J. Child Neurol. 15(10), 702–704.
< , H., Yamazaki, S., Abe, T., Oda, Y. (https://doi.org/10.1177/088307380001501014>